A study of 28 pregnant women with sickle cell disease and COVID-19: elevated maternal and fetal morbidity rates

Affiliations

• ¹ Biotherapy Department, French National Sickle Cell Disease Referral Center, Clinical Investigation Center, Hopital Necker, Labex GR-Ex, Assistance-Publique Hopitaux de Paris, Paris. laure.joseph@aphp.fr.
• ² Unite des maladies genetiques du globule rouge and Etablissement Francais du Sang, Hopital Henri Mondor, Assistance-Publique Hopitaux de Paris, Creteil.
• ³ Antilles-Guyane Reference Center for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, Pointe a Pitre, Guadeloupe.
• ⁴ Institut Universitaire du Cancer Toulouse Oncopole, Medecine Interne, Toulouse.
• ⁵ Department of Internal Medicine, Reference Center of Sickle cell Anemia, University Hospital Center of Tenon, Sorbonne University, Assistance-Publique Hopitaux de Paris, Paris.
• ⁶ Department of Internal Medicine, Aix Marseille Universite, Assistance-Publique Hopitaux de Marseille, Hopital de la Timone, Marseille.
• ⁷ Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, Assistance-Publique Hopitaux de Paris, U-PEC, Creteil.
• ⁸ Sickle Cell Referral Center, Centre Hospitalier de Mayotte, Mayotte.
• ⁹ Sickle Cell Referral Center, Martinique Hospital, Martinique.
• ¹⁰ Biotherapy Department, French National Sickle Cell Disease Referral Center, Clinical Investigation Center, Hopital Necker, Labex GR-Ex, Assistance-Publique Hopitaux de Paris, Paris.
• ¹¹ Internal Medicine Department, French National Sickle Cell Disease Referral Center, Georges Pompidou European Hospital, Assistance Publique-Hopitaux de Paris, Paris.